Scientists have shown that a compound called PHT-7.3 shrinks KRAS-driven tumors in mice. In contrast to directly targeting mutant KRAS, the potential drug candidate targets the protein’s partner in crime: the cellular scaffold to which mutated KRAS attaches.
Click here for original story, Conquering cancer’s infamous KRAS mutation
Source: ScienceDaily